Cargando…
Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
BACKGROUND: To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP). METHODS: VALIDATE-J, a multicenter, cross-sectional, retrospective study, r...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548573/ https://www.ncbi.nlm.nih.gov/pubmed/37789253 http://dx.doi.org/10.1186/s12879-023-08466-8 |
_version_ | 1785115296742244352 |
---|---|
author | Hase, Ryota Suzuki, Daisuke de Luise, Cynthia Chen, Haoqian Nonnenmacher, Edward Higuchi, Takakazu Katayama, Kayoko Kinjo, Mitsuyo Jinno, Sadao Morishima, Toshitaka Sugiyama, Naonobu Tanaka, Yoshiya Setoguchi, Soko |
author_facet | Hase, Ryota Suzuki, Daisuke de Luise, Cynthia Chen, Haoqian Nonnenmacher, Edward Higuchi, Takakazu Katayama, Kayoko Kinjo, Mitsuyo Jinno, Sadao Morishima, Toshitaka Sugiyama, Naonobu Tanaka, Yoshiya Setoguchi, Soko |
author_sort | Hase, Ryota |
collection | PubMed |
description | BACKGROUND: To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP). METHODS: VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012–2016. Diagnosis was confirmed with three gold standard definitions; positive predictive values (PPVs) were calculated for prevalent (regardless of baseline disease-free period) and incident (preceded by a 12-month disease-free period for the target conditions) cases. RESULTS: Of patients identified using claims-based algorithms, a random sample of 377 cases was included: HZ (n = 95 [55 incident cases]); MTB (n = 100 [58]); NTM (n = 82 [50]); and PJP (n = 100 [84]). PPVs ranged from 67.4–70.5% (HZ), 67.0–90.0% (MTB), 18.3–63.4% (NTM), and 20.0–45.0% (PJP) for prevalent cases, and 69.1–70.9% (HZ), 58.6–87.9% (MTB), 10.0–56.0% (NTM), and 22.6–51.2% (PJP) for incident cases, across definitions. Adding treatment to the algorithms increased PPVs for HZ, with a small increase observed for prevalent cases of NTM. CONCLUSIONS: VALIDATE-J demonstrated moderate to high PPVs for disease-identifying algorithms for HZ and MTB using Japanese claims data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08466-8. |
format | Online Article Text |
id | pubmed-10548573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105485732023-10-05 Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan Hase, Ryota Suzuki, Daisuke de Luise, Cynthia Chen, Haoqian Nonnenmacher, Edward Higuchi, Takakazu Katayama, Kayoko Kinjo, Mitsuyo Jinno, Sadao Morishima, Toshitaka Sugiyama, Naonobu Tanaka, Yoshiya Setoguchi, Soko BMC Infect Dis Research BACKGROUND: To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP). METHODS: VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012–2016. Diagnosis was confirmed with three gold standard definitions; positive predictive values (PPVs) were calculated for prevalent (regardless of baseline disease-free period) and incident (preceded by a 12-month disease-free period for the target conditions) cases. RESULTS: Of patients identified using claims-based algorithms, a random sample of 377 cases was included: HZ (n = 95 [55 incident cases]); MTB (n = 100 [58]); NTM (n = 82 [50]); and PJP (n = 100 [84]). PPVs ranged from 67.4–70.5% (HZ), 67.0–90.0% (MTB), 18.3–63.4% (NTM), and 20.0–45.0% (PJP) for prevalent cases, and 69.1–70.9% (HZ), 58.6–87.9% (MTB), 10.0–56.0% (NTM), and 22.6–51.2% (PJP) for incident cases, across definitions. Adding treatment to the algorithms increased PPVs for HZ, with a small increase observed for prevalent cases of NTM. CONCLUSIONS: VALIDATE-J demonstrated moderate to high PPVs for disease-identifying algorithms for HZ and MTB using Japanese claims data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08466-8. BioMed Central 2023-10-03 /pmc/articles/PMC10548573/ /pubmed/37789253 http://dx.doi.org/10.1186/s12879-023-08466-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hase, Ryota Suzuki, Daisuke de Luise, Cynthia Chen, Haoqian Nonnenmacher, Edward Higuchi, Takakazu Katayama, Kayoko Kinjo, Mitsuyo Jinno, Sadao Morishima, Toshitaka Sugiyama, Naonobu Tanaka, Yoshiya Setoguchi, Soko Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan |
title | Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan |
title_full | Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan |
title_fullStr | Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan |
title_full_unstemmed | Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan |
title_short | Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan |
title_sort | validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in japan |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548573/ https://www.ncbi.nlm.nih.gov/pubmed/37789253 http://dx.doi.org/10.1186/s12879-023-08466-8 |
work_keys_str_mv | AT haseryota validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT suzukidaisuke validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT deluisecynthia validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT chenhaoqian validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT nonnenmacheredward validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT higuchitakakazu validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT katayamakayoko validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT kinjomitsuyo validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT jinnosadao validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT morishimatoshitaka validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT sugiyamanaonobu validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT tanakayoshiya validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan AT setoguchisoko validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan |